• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Metastatic prostate cancer patients who have not received chemotherapy survive longer on abiraterone plus prednisone

bys25qthea
January 20, 2014
in Chronic Disease, Oncology, Surgery
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Image: CC. Histology of prostate cancer. 

1.     Patients with metastatic castration-resistant prostate cancer survived longer on abiraterone plus prednisone vs. on prednisone alone.

2.    Abiraterone plus prednisone increased the time to radiographic progression compared to patients taking prednisone alone.

Primer: Prostate cancer is the most common cancer in men and it is the second most common cause of death from cancer among men.  Screening tests for this cancer have limitations, and several patients present with metastatic prostate cancer.

Standard medical treatment includes long acting GnRH analogs and anti-androgen receptor antagonists, which shut down the production of testosterone, an important signal for growth for prostate cancer. However, some cancers are able to produce their own testosterone and can no longer be treated in this fashion – these are termed castration-resistant.

Abiraterone is a drug that inhibits the enzyme cyp17, which is important in the production of testosterone. It has been shown to decrease symptoms as well as increase survival in patients with metastatic castration-resistant prostate cancer after chemotherapy with docetaxel.

Many providers eschew chemotherapy because of its limited benefits in this setting. Therefore, this study sought to determine whether metastatic castration-resistant prostate cancer patients would benefit from abiraterone plus prednisone without prior chemotherapy.

RELATED REPORTS

Rocatinlimab may be effective in the treatment of moderate-to-severe atopic dermatitis

Gender-affirming hormones improve psychosocial functioning in transgender youth

Left atrial reservoir strain improves ischemic stroke risk prediction in low-risk patients

Background reading: 

  1. CDC Prostate Cancer Fast Facts
  2. Abiraterone and Increased Survival in Metastatic Prostate Cancer

This [phase 3 double blind randomized controlled] study evaluated the use of abiraterone plus prednisone versus prednisone alone in men with metastatic castration-resistant prostate cancer who have not received chemotherapy and do not have cancer-related symptoms.

Patients who received abiraterone plus prednisone demonstrated delayed the progression of radiographic findings (soft tissue extension) by 8.2 months compared to those patients taking prednisone alone (16.5 vs 8.3 months, p<0.001). Furthermore, patients on abiraterone had longer latency periods for initiation of opiates, PSA progression, treatment with chemotherapy as well as decline in quality of life. Lastly, the data showed a positive trend toward increased survival. As a result, the trial was unblinded and patients in the prednisone alone group were moved to the abiraterone group.

In sum: Abiraterone plus prednisone appears to decrease progression while ameliorating symptoms and improving quality of life, and might also increase survival, in patients with metastatic castration-resistant prostate cancer.

This large study included patients from several countries. As very few therapies besides cytotoxic chemotherapy have been shown to increase patient survival, these promising results might prompt changes in the current management of metastatic prostate cancer.

Click to read the study in NEJM

By [JC] and [MP]

© 2013 2minutemedicine.com. All rights reserved. No works may be reproduced without written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT. Content is produced in accordance with fair use copyrights solely and strictly for the purpose of teaching, news and criticism. No benefit, monetary or otherwise, is realized by any participants or the owner of this domain. 

Previous Post

[Physician Comment] An argument against hospital admission for heart failure

Next Post

[Policy Statement] Vaccines safe, Institute of Medicine reports

RelatedReports

Topical pimecrolimus use for atopic dermatitis not linked to malignancy
Chronic Disease

Rocatinlimab may be effective in the treatment of moderate-to-severe atopic dermatitis

January 31, 2023
Mental health parity law associated with financial protection for children
Endocrinology

Gender-affirming hormones improve psychosocial functioning in transgender youth

January 31, 2023
Intensive rehabilitation not superior to traditional therapy for arm function after stroke
Cardiology

Left atrial reservoir strain improves ischemic stroke risk prediction in low-risk patients

January 31, 2023
#VisualAbstract: Switch to fulvestrant and palbociclib may improve survival in patients with advanced breast cancer and ESR1 mutation
StudyGraphics

#VisualAbstract: Switch to fulvestrant and palbociclib may improve survival in patients with advanced breast cancer and ESR1 mutation

January 31, 2023
Next Post

[Policy Statement] Vaccines safe, Institute of Medicine reports

[Physician Comment] Early antiretroviral therapy in HIV linked with increased likelihood of CD4+ recovery

Early initiation of antiretroviral therapy linked with lower risk of cognitive impairment in HIV

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Rocatinlimab may be effective in the treatment of moderate-to-severe atopic dermatitis
  • Gender-affirming hormones improve psychosocial functioning in transgender youth
  • Left atrial reservoir strain improves ischemic stroke risk prediction in low-risk patients
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options